HK1044887A1 - 利用腫瘤壞死因子α(TNF-α)及血管內皮生長因子(VEGF)製造一種治療成份 - Google Patents

利用腫瘤壞死因子α(TNF-α)及血管內皮生長因子(VEGF)製造一種治療成份

Info

Publication number
HK1044887A1
HK1044887A1 HK02105101.3A HK02105101A HK1044887A1 HK 1044887 A1 HK1044887 A1 HK 1044887A1 HK 02105101 A HK02105101 A HK 02105101A HK 1044887 A1 HK1044887 A1 HK 1044887A1
Authority
HK
Hong Kong
Prior art keywords
alpha
vegf
tnf
manufacture
vascular endothelial
Prior art date
Application number
HK02105101.3A
Other languages
English (en)
Inventor
Feldmann Marc
Nath Maini Ravinder
Maria Paleolog Ewa
Original Assignee
The Kennedy Inst Of Rheumatology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Kennedy Inst Of Rheumatology filed Critical The Kennedy Inst Of Rheumatology
Publication of HK1044887A1 publication Critical patent/HK1044887A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK02105101.3A 1997-05-12 2002-07-09 利用腫瘤壞死因子α(TNF-α)及血管內皮生長因子(VEGF)製造一種治療成份 HK1044887A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85488197A 1997-05-12 1997-05-12

Publications (1)

Publication Number Publication Date
HK1044887A1 true HK1044887A1 (zh) 2002-11-08

Family

ID=25319772

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02105101.3A HK1044887A1 (zh) 1997-05-12 2002-07-09 利用腫瘤壞死因子α(TNF-α)及血管內皮生長因子(VEGF)製造一種治療成份

Country Status (6)

Country Link
EP (2) EP1170017A1 (zh)
JP (1) JP2001525816A (zh)
AU (1) AU7345798A (zh)
CA (1) CA2290021A1 (zh)
HK (1) HK1044887A1 (zh)
WO (1) WO1998051344A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
CA2317839A1 (en) 1998-01-22 1999-07-29 Btg International Limited Inhibition of cytokine production
WO2000051637A1 (en) * 1999-03-02 2000-09-08 Centocor, Inc. ANTI-TNFα ANTIBODIES IN THERAPY OF ASTHMA
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EP1259616A2 (en) * 2000-03-02 2002-11-27 Xencor Tnf-alpha variants for the treatment of tnf-alpha related disorders
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US7244823B2 (en) 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7687461B2 (en) 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US7662367B2 (en) 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20040136991A1 (en) * 2002-07-19 2004-07-15 Abbott Biotechnology Ltd. Treatment of anemia using TNFalpha inhibitors
KR20050056247A (ko) 2002-10-15 2005-06-14 셀진 코포레이션 골수형성이상증후군의 치료 및 관리를 위한 선택적인사이토킨 저해 약물의 사용 방법 및 이를 포함하는 조성물
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
EP1660504B1 (en) 2003-08-29 2008-10-29 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
WO2005041877A2 (en) * 2003-10-29 2005-05-12 Children's Medical Center Corporation Method of inhibiting rejection following organ transplantation
NZ547009A (en) 2003-12-23 2009-09-25 Pfizer Novel quinoline derivatives
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
TWI399384B (zh) 2005-05-16 2013-06-21 Abbott Biotech Ltd ＴＮＦα抑制劑於治療侵蝕型多發性關節炎之用途
JP2008120722A (ja) * 2006-11-10 2008-05-29 Benesis Corp 生物由来製品の偽薬
JP5732039B2 (ja) * 2009-03-20 2015-06-10 アンタレス・ファーマ・インコーポレーテッド 危険有害性薬剤の注入システム
JP2014518758A (ja) 2011-05-06 2014-08-07 バイオ−ラッド ラボラトリーズ インコーポレーティッド 迅速な温度変化のためのベイパーチャンバーを備えたサーマルサイクラー

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU668864B2 (en) * 1991-03-18 1996-05-23 Centocor Inc. Chimeric antibodies specific for human tumor necrosis factor
WO1994006476A1 (en) * 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
DE69233739D1 (de) * 1992-10-28 2008-08-07 Genentech Inc Verwendung von Antagonisten des Zellwachstumsfaktors VEGF
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists

Also Published As

Publication number Publication date
JP2001525816A (ja) 2001-12-11
AU7345798A (en) 1998-12-08
EP0980258A1 (en) 2000-02-23
WO1998051344A1 (en) 1998-11-19
CA2290021A1 (en) 1998-11-19
EP1170017A1 (en) 2002-01-09

Similar Documents

Publication Publication Date Title
HK1044887A1 (zh) 利用腫瘤壞死因子α(TNF-α)及血管內皮生長因子(VEGF)製造一種治療成份
EP1045636A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD OF USING THE SAME FOR TREATING FAILURE MYOCARDIAL TISSUES
HK1105580A1 (en) Use of isoflavone compounds in the manufacture of medicament and composition comprising the same
EE04852B1 (et) C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
EP1025228A4 (en) HUMAN PROTEIN TR11, TR11SV1 AND TR11SV2 SIMILAR TO THE TUMOR NECROSIS FACTOR RECEPTOR
EP1227821A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD FOR USE THEREOF
AU3242693A (en) Pads, methods of making, and methods of use for wound dressing, surgical reinforcement and hemostasis promotion
AU3947902A (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
HK1092380A1 (en) Use of plant extract in the manufacture of a medicament for treating diseases of increase bone resorption and composition thereof
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
HUP1500179A2 (en) The use of human tnf-alpha binding antibodies
AU7031500A (en) Therapeutic quinazoline compounds
IL141403A0 (en) Deleted adenoviruses and methods of making and administering the same
ZA987676B (en) 3-amidinoaniline derivatives activated blood coagulation factor X inhibitors and intermediates thereof
HUP9902867A3 (en) Therapeutic use of vegf protein or nucleic acid coding same and implant, especially for the treatment of intimal hyperplasia
AU7830398A (en) Human tumor necrosis factor receptor tr9
HUP0202862A3 (en) Pharmaceutical composition containing novel combination of loteprednol and antihistamines
AU7705098A (en) Human tumor necrosis factor receptor-like protein 8
PL347659A1 (en) Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
AU3766700A (en) Human tumor necrosis factor receptor-like 2
EP0961782A4 (en) TR2 RECEPTOR OF TUMOR NECROSIS FACTOR IN MAN
GB9611180D0 (en) Treatment of vascular lesions
IL121329A (en) Pharmaceutical composition for the treatment of cancer comprising somatostatin2 and other peptides
AU2002253785A1 (en) Catheter and implants for the delivery of therapeutic agents to tissues